Home › Companies › Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. (MLYS) proxy voting records

How asset managers voted at Mineralys Therapeutics, Inc.’s shareholder meetings, one page per proxy season, compiled from the votes funds and managers report on SEC Form N-PX and the company’s own results on Form 8-K.

TickerMLYS
CUSIP issuer number603170
SEC CIK1933414

Recent shareholder votes

May 21, 2026 annual meeting (2025-2026 proxy season): 4 items in Mineralys Therapeutics, Inc.'s official results (Form 8-K, filed May 22, 2026); lowest support 61% of votes cast (Elect Director: Srinivas Akkaraju, M.D., Ph.D.). Full results and how funds voted.

Each line is the company’s own Form 8-K tally as shown on that season’s page; support is FOR as a share of votes cast.

Proxy seasons

Season	Filed as	Ballot items	Asset managers
2025-2026	Mineralys Therapeutics, Inc.	4	73

Explore Mineralys Therapeutics, Inc. in the interactive database

The seasons are grouped by the issuer number in the company’s CUSIP, not by its name. Ticker as listed by the SEC on November 6, 2026. This page is rebuilt weekly; built November 9, 2026.